Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24704673 | 0.98 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL18520254 | 0.98 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL11858592 | 0.98 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL24704621 | 0.98 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL19245329 | 0.98 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL27540335 | 0.96 | EPHX1 (0.40) | EPHX1SIGMAR1EPHX2CYP1A2 | |
| SCHEMBL20747001 | 0.96 | SIGMAR1 (0.42) | EPHX1SIGMAR1EPHX2MEN1KMT2A | |
| SCHEMBL22355901 | 0.96 | SIGMAR1 (0.42) | EPHX1SIGMAR1EPHX2MEN1KMT2A | |
| SCHEMBL28747291 | 0.94 | SIGMAR1 (0.42) | EPHX1SIGMAR1EPHX2KMT2ANAAA | |
| SCHEMBL11298979 | 0.94 | SIGMAR1 (0.42) | EPHX1SIGMAR1EPHX2KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20180111913-A1 | SUBSTITUTED BENZOFURAN DERIVATIVES AS NOVEL ANTIMYCOBACTERIAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | EPHX1 3368/4885SIGMAR1 3726/4885EPHX2 4188/4885 |
| US-20180111913-A1 | SUBSTITUTED BENZOFURAN DERIVATIVES AS NOVEL ANTIMYCOBACTERIAL AGENTS | ACAT1, ACAT2, FNTB | EPHX1 3534/4885SIGMAR1 3728/4885EPHX2 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.